{
  "company": {
    "name": "Kinaset Therapeutics",
    "website": "https://kinasettherapeutics.com/",
    "record": "https://startuphistory.org/c/kinasettherapeutics.com"
  },
  "status": null,
  "history_since": "2020-11-30T12:03:13.000Z",
  "baseline": {
    "snapshot_id": "6c2b96ad8f861fe06d6af098b377a7b58b83a144a4523b6c6574d116424575d5",
    "observed_at": "2022-01-10T04:40:06.000Z",
    "headline": "Developing inhaled therapeutics in respiratory diseases",
    "description": "DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.",
    "evidence": "https://web.archive.org/web/20220110044006/https://www.kinasettherapeutics.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-06T17:29:37.533Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2026-11-06T17:29:37.533Z",
      "variants": [
        {
          "headline": "Developing inhaled therapeutics in respiratory diseases",
          "subhead": "DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.",
          "observed_at": "2022-01-10T04:40:06.000Z",
          "evidence": "https://web.archive.org/web/20220110044006/https://www.kinasettherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Developing inhaled therapeutics in respiratory diseases",
          "subhead": "DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.",
          "observed_at": "2022-07-10T14:27:33.000Z",
          "evidence": "https://web.archive.org/web/20220710142733/https://www.kinasettherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Developing inhaled therapeutics in respiratory diseases",
          "subhead": "DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.",
          "observed_at": "2023-05-16T00:43:06.000Z",
          "evidence": "https://web.archive.org/web/20230516004306/https://www.kinasettherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Developing inhaled therapeutics in respiratory diseases",
          "subhead": "DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.",
          "observed_at": "2023-10-08T09:07:28.000Z",
          "evidence": "https://web.archive.org/web/20231008090728/https://www.kinasettherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Developing inhaled therapeutics in respiratory diseases",
          "subhead": "DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.",
          "observed_at": "2024-01-01T21:30:55.000Z",
          "evidence": "https://web.archive.org/web/20240101213055/https://www.kinasettherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Developing inhaled therapeutics in respiratory diseases",
          "subhead": "DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.",
          "observed_at": "2025-01-11T05:29:42.000Z",
          "evidence": "https://web.archive.org/web/20250111052942/https://www.kinasettherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Developing inhaled therapeutics in respiratory diseases",
          "subhead": "DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.",
          "observed_at": "2026-01-11T06:54:57.000Z",
          "evidence": "https://web.archive.org/web/20260111065457/https://www.kinasettherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Developing inhaled therapeutics in respiratory diseases",
          "subhead": "DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.",
          "observed_at": "2026-11-06T17:29:37.533Z",
          "evidence": "https://www.kinasettherapeutics.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Developing inhaled therapeutics in respiratory diseases",
      "subhead": "DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.",
      "from": "2022-01-10T04:40:06.000Z",
      "to": "2026-11-06T17:29:37.533Z",
      "captures": 8,
      "evidence": "https://www.kinasettherapeutics.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2022-01-10T04:40:06.000Z",
          "to": "2026-11-06T17:29:37.533Z"
        }
      },
      "current": true
    }
  ],
  "changes": [],
  "update": null,
  "same_space": [
    {
      "name": "Aspiro Therapeutics",
      "record": "https://startuphistory.org/c/aspirotx.com",
      "basis": "description_similarity",
      "category": null
    },
    {
      "name": "Attune Pharmaceuticals",
      "record": "https://startuphistory.org/c/attunepharma.com",
      "basis": "description_similarity",
      "category": null
    },
    {
      "name": "Kestrel Therapeutics",
      "record": "https://startuphistory.org/c/kestreltherapeutics.com",
      "basis": "description_similarity",
      "category": null
    },
    {
      "name": "Ajax Therapeutics",
      "record": "https://startuphistory.org/c/ajaxtherapeutics.com",
      "basis": "description_similarity",
      "category": null
    },
    {
      "name": "Celea Therapeutics",
      "record": "https://startuphistory.org/c/celeatx.com",
      "basis": "description_similarity",
      "category": null
    }
  ],
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Kinaset Therapeutics” company record, https://startuphistory.org/c/kinasettherapeutics.com"
}